Cytek Biosciences, Inc. - 8-K Filing

Cytek Biosciences reports Q3 2026 revenue of $53.2 million and maintains full-year guidance range of $208M to $211M. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $CTKB

Read the full article at SEC EDGAR

More Regulatory news